Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma

20260 citationsJournal Articlehybrid Open Access

Authors

Catherine Thieblemont · Assistance Publique – Hôpitaux de Paris

F. Colrat · Bristol-Myers Squibb (France)

R. Sellami · Total (France)

Marine Sivignon · Total (France)

Adrien Petel · Bristol-Myers Squibb (France)

S. Branchoux · Bristol-Myers Squibb (France)

de Pouvourville G ·

Abstract

Liso-cel is cost-effective versus SOC to treat R/R LBCL patients in France. Generation of long-term real-world data is needed in order to validate these findings.

Topics & Keywords

Lymphoma Diagnosis and Treatment CAR-T cell therapy research Chronic Lymphocytic Leukemia Research

Publication Details

Published in: European Journal Of Haematology

DOI: 10.1111/ejh.70131

Field-Weighted Citation Impact: 0.00

Command Palette

Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma

Authors

Abstract

Topics & Keywords

Publication Details